If patient presents symptoms eg, blurred vision or other visual disturbances, consider referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases (eg, central serous chorioretinopathy). Prolonged treatment may exhibit atrophic facial changes. Avoid contact w/ eyes. W/draw if there is any spread of infection. Pregnancy. Avoid long-term continuous therapy where possible particularly in infants & childn due to the risk of adrenal suppression.
Blurred vision. Prolonged & intensive use: May cause local atrophic skin changes [eg, striae, thinning & dilatation of superficial blood vessels (particularly when occlusive dressings are used or when skin folds are involved)]; hypercorticism features (more likely in infants & childn).
Exemptions granted for limited sale and supply without prescription (with effect from 31 March 2016):
As a topical preparation (as valerate or dipropionate salt) and as a single agent not exceeding 0.1%
Indication: Symptomatic relief of inflammatory skin or scalp disorders such as dermatitis and eczema
Maximum daily dose: Apply to affected areas twice daily
Maximum supply: 15 g for cream/ointment/gel; 30 mL for topical solution
Minimum age: 18 years
Presentation/Packing
Form
Medobeta cream 0.1 %
Packing/Price
15 g x 1's
Form
Medobeta oint 0.1 %
Packing/Price
15 g x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign Out
